 |
|
|
| |
A COST-EFFECTIVENESS ANALYSIS OF LDV/SOF+RBV FOR 12 WEEKS VS. LDV/SOF 24 WEEK VS. SOF+SMV 24 WEEKS IN CHC GT1 TE CIRRHOTIC PATIENTS
|
| |
| |
Reported by Jules Levin
DDW 2015 - May 16-19 Wash DC
Ahmed, A1; Dieterich, DT2; Park, H3; Saab, S4; Gordon, SC5; Younossi, ZM6
References
1.Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, Giuily N, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008;135:821-829.
2.Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-337.
3.D'Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, Colombo M, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012;56:532-543.
4.Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997;27:201-205.
5.Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-865.
6.Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006;43:1303-1310.
7.Liu J, Wang Y, Zhang D, Liu B, Ou Q. Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. Eur J Gastroenterol Hepatol 2012;24:186-194.
8.Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013;57:2164-2170.
References
1.Bourliere M, Bronowicki JP, et al. Ledipasvir / sofosbuvir fixed-dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. AASLD 2014 Nov 7-11, Boston, MA.
2.Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection (ION-II). N Engl J Med 2014a;370:1483-1493.
3.Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014.
4.McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Making 2008;28:582-592.
5.Wright NM, Tompkins CN. A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users. Harm Reduct J 2006;3:27.
6.Hsu PC, Federico CA, Krajden M, Yoshida EM, Bremner KE, Anderson FH, Weiss AA, et al. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol 2012;27:149-157.
7.Younossi ZM, Henry L. Systematic review : patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015; doi: 10.1111/apt.13090.
Assumption validated by national panel of hepatologists.
References
1.RedBook. Red Book Online. Micromedex 2.0; 2014.
2.Gordon SC, Hamzeh FM, Pockros PJ, Hoop RS, Buikema AR, Korner EJ, Terrault NA. Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther 2013a;38:784-793.
3.McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011;17:531-546.
4.Assumption validated by a national panel of hepatologists.
5.Catana AM, Tapper E, Mansuri D, Sethi N, Vong A, Sethi S, Afdhal NH. Direct Costs of Care for Hepatocellular Carcinoma in Patients with Hepatitis C Cirrhosis. AASLD 2014 Nov 7-11, Boston, MA.
|
| |
|
|
|
|
|
